Evidence map›Paper›PMID 42303761›Full record

ArticleNPJ precision oncology2026

Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors.

Gerhard Jungwirth, Adrian Paul, Amélie Wöllner, Rolf Warta, Junguo Cao, Valentina Fermi, Lena Jassowicz, Philip Dao Trong, Andreas von Deimling, Juergen Debus and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gerhard JungwirthDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Adrian PaulDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Amélie WöllnerDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Rolf WartaDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Junguo CaoDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Valentina FermiDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Lena JassowiczDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Philip Dao TrongDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, Heidelberg University, Heidelberg, Germany.
Juergen DebusGerman Cancer Consortium (DKTK) Core-Center Heidelberg, Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sandro KriegDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Andreas UnterbergDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Amir AbdollahiGerman Cancer Consortium (DKTK) Core-Center Heidelberg, Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christel Herold-MendeDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany. H.Mende@med.uni-heidelberg.de.

Funding

China Scholarship Council 201906170055
6 · The paper itself

Abstract

Personalized drug screening aims to improve the survival of glioblastoma (GBM) patients by identifying effective patient-individual drugs. Therefore, we conducted an automated high-throughput drug screening (aHTS) on standardized patient-derived glioblastoma tumor organoids (TOs). Robot-assisted aHTS was performed on TOs from 11 GBM patients. TOs fully compacted after two days, and the size remained stable over 10 days. TOs proliferated over time, and immunofluorescence stainings (GFAP, Tenascin C) confirmed tissue-like architecture. Anti-glioma effects with the lowest drug concentrations were achieved for proteasome inhibitors (carfilzomib, bortezomib, ixazomib), and HDAC inhibitors (panobinostat, romidepsin). Plasma C

Identifiers

PMID42303761
PMCPMC13273099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.